Table 1.
Characteristics of the studies included
| Study, year | Design | Inclusion Criteria | Outcomes | Atosiban dose |
|---|---|---|---|---|
| Moraloglu et al., 2010 | Prospective, randomized, placebo-controlled clinical study | Women undergoing intracytoplasmic sperm injection who had top-quality embryos | Clinical pregnancy rate per cycle and implantation rate | Intravenous atosiban 30 min before the embryo transfer with a bolus dose of 6.75 mg, and the infusion was continued with an infusion rate of 18 mg/h. After performing embryo transfer, the dose of atosiban was reduced to 6 mg/h and the infusion was continued for 2 h (total administered dose: 37.5 mg). |
| Chou et al., 2011 | Retrospective cohort study | Repeated implantation failure (RIF) | Implantation rate, clinical pregnancy rate, live birth rate | Forty patients received a single bolus dose (6.75 mg, 0.9 mL/vial) of atosiban before ET (Group 2), and 30 patients received a bolus dose of 6.75 mg atosiban followed by infusion at 18 mg/hr. for 3 hours immediately after ET (Group 3). |
| Lan et al., 2012 | Prospective cohort study | Women with repeated implantation failure | Uterine contraction, implantation rate (IR) and clinical pregnancy rate (CPR) | I.V. bolus of 6.75 mg at 30 min prior to embryo transfer followed by i.v. infusion at a rate of 18 mg/h for 1h and 6 mg/h for the subsequent 2h. The total dose administered was 36.75 mg. |
| Ng et al., 2014 | Multi-center randomized double blind study | Consecutive subfertile women undergoing IVF treatment | The primary outcome measure was the live birth rate and the secondary outcome measures including positive pregnancy test, clinical pregnancy, ongoing pregnancy, miscarriage, multiple pregnancy and ectopic pregnancy rates. | I.V. Atosiban 30 min before the transfer with a bolus dose of 6.75 mg, and the infusion was continued at a rate of 18 mg/h for 1h. The dose of Atosiban was then reduced to 6 mg/h after embryo transfer and the infusion was continued for another 2h. Therefore, the total administered dose was 37.5 mg. |
| He et al., 2016a | Randomized, controlled clinical trial. | Women with endometriosis undergoing frozen–thawed embryo transfer | Implantation rate and pregnancy rate. | IV bolus of 6.75 mg at approximately 30 min before ET. |
| He et al., 2016b | Prospective cohort study | Patients undergoing IVF/ET using cryopreserved embryos | Uterine contraction, clinical pregnancy rate | I.V. bolus of 6.75 mg at about 30 min prior before ET. |
| Hebisha et al., 2016 | Randomized controlled trial. | One hundred and eighty two women, prepared for intracytoplasmic sperm injection for male or tubal factor infertility, using long agonist protocol | Pregnancy rate, implantation rate. | 7.5 mg Atosiban by slow IV injection |